Brought to you by 
Follow-on nets Sorrento Therapeutics $32.2mm
30 Oct 2013
Executive Summary
Just weeks after buying pain therapeutics start-up Sherrington Pharmaceuticals, Sorrento Therapeutics Inc. (in-licenses candidates for cancer, inflammation, metabolic, and infectious diseases) netted $32.2mm by selling to public investors 4.8mm shares (including the overallotment) for $7.25. The financing is concurrent with the company's listing on Nasdaq (it will cease trading on the OTCQB).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Follow-on nets Sorrento Therapeutics $32.2mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice